SCHEMBL25031335

SCHEMBL25031335

CCC1(O)CCc2ccc(N)nc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
GABRA4 P48169 1/20 0.33
GABRE P78334 1/20 0.33
GABRA6 Q16445 1/20 0.33
GABRG1 Q8N1C3 1/20 0.33
GABRG3 Q99928 1/20 0.33
GABRQ Q9UN88 1/20 0.33
WEE1 P30291 5/20 0.31
MAP3K14 Q99558 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29310253 0.90 DRD2 (0.33) DRD2DRD3GABRPGABRDGABRA1
SCHEMBL29310262 0.89 DRD2 (0.35) DRD2DRD3GABRPGABRDGABRA1
SCHEMBL22532060 0.85 MAP3K14 (0.38) WEE1MAP3K14EGFRCYP3A4PLK1
SCHEMBL30496896 0.85 MAP3K14 (0.38) WEE1MAP3K14EGFRCYP3A4PLK1
SCHEMBL23364873 0.85 MAP3K14 (0.38) WEE1MAP3K14EGFRCYP3A4PLK1
SCHEMBL29828611 0.85 MAP3K14 (0.38) WEE1MAP3K14EGFRCYP3A4PLK1
SCHEMBL24881427 0.81 MAP3K14 (0.32) WEE1MAP3K14EGFRCYP3A4PLK1
SCHEMBL21334000 0.81 MAP3K14 (0.32) WEE1MAP3K14EGFRCYP3A4PLK1
SCHEMBL23364874 0.81 MAP3K14 (0.32) WEE1MAP3K14EGFRCYP3A4PLK1
SCHEMBL21349674 0.81 MAP3K14 (0.32) WEE1MAP3K14EGFRCYP3A4PLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2024-07-11 US disclosed
WO-2023030388-A1 5-FLUORO-7H-PYRROLO[2,3-D] PYRIMIDINES COMPOUND AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2023-03-09 WO disclosed
WO-2023016417-A1 1,2-DIHYDRO-3H-PYRAZOL[3,4-D]PYRIMIDIN-3-ONE COMPOUND AS WEE-1 INHIBITOR 微境生物医药科技(上海)有限公司 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228459-A1 WEE1 INHIBITORS AND USES THEREOF WEE1, WEE2, DCLRE1B DRD2 4849/4885DRD3 4775/4885GABRP 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.